Next Investors logo grey

City of Hope receives US DoD grant with upside for Imugene


Published 23-OCT-2019 11:07 A.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

A US Department of Defense Grant titled Discovery of Immune Biomarkers That Predict Response to a Novel Chimeric Immuno-Oncolytic Virus Encoding Anti-PD-L1 in Gastric Cancer Peritoneal Carcinomatosis has been awarded to prominent City of Hope researchers.

The grant US$564,173 was awarded to Yanghee Woo, MD, Associate Clinical Professor, Department of Surgery and Director, Gastroenterology Minimally Invasive Therapy Program, together with Yuman Fong, MD, Professor and Chair of the Department of Surgery.

Professor Fong is an internationally recognised expert in liver and pancreatic cancer. He has developed several surgical techniques and instruments and has also led research efforts to use genetically modified viruses to destroy cancer cells. Dr. Woo is a City of Hope surgeon-scientist specially trained and internationally recognised in robotic surgery and gastric cancer.

City of Hope is a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based near Los Angeles.

City of Hope is working closely with Australian clinical stage immuno-oncology company Imugene Limited (ASX:IMU) in the fight against cancer.

Imugene currently has a proposal on the table to license CF33 from City of Hope. The CF33 oncolytic virus (OV) technology was developed in the laboratory of Professor Fong and as we pointed out in a previous Finfeed article has been developed in two different constructs.

One version of the OV is “armed” with an immune checkpoint inhibitor inserted in the virus, which is known as CheckVacc.

The other is an unarmed construct, known as Vaxinia.

Imugene plans to conduct two separate Phase 1 clinical trials in 2020 to test a CheckVacc construct and a Vaxinia construct of the OV.

What is CF33

The CF33 Oncolytic Chimeric Poxvirus Oncolytic virotherapy (OV) utilises naturally occurring or genetically modified viruses to infect, replicate in, and kill cancer cells, while sparing healthy cells.

The first OV for human therapy was recently approved by the US Food and Drug Administration (FDA): T-VEC (talimogene laherparepvec, Amgen), for the treatment of

metastatic melanoma.

Preclinical data has demonstrated that CF33 is more efficacious than all parental viruses and some viruses in clinical trials. CF33 efficiently shrank injected tumours and distant non-injected tumours in human triple negative breast cancer, colon cancer, ovarian cancer xenograft models in mice without adverse effects at a dose that is 2-5 orders of magnitude lower than doses used for oncolytic viruses under clinical testing.

Especially impressive is that CF33 can shrink multiple types of cancer at an extremely low dose (1000 PFU). Importantly, CF33 shrinks not only injected tumours, but also non-injected distant tumours (abscopal effect). CF33 showed superior replication and cancer cell killing in NCI-60 cell lines and is more potent than all the parental and competitor viruses in most of the NCI-60 cell lines except for a few cell lines in which none of the viruses showed any effect at the low MOI (0.01).

Focus of the grant

US Department of Defense Grant focuses on the area of stomach (gastric) cancer (GC), a disease that disproportionately affects US military service members, veterans, and their beneficiaries who have increased exposure to hazardous environmental risk factors, such as H. pylori, Epstein-Barr viral infections, radiation, and tobacco smoking.

Peritoneal carcinomatosis (PC) is a fatal evolution of GC for which there is no effective treatment. Across military families and the general population, over 60% of all patients with GC will develop peritoneal disease as the most common manifestation of recurrence or metastatic presentation.

The progression of primary GC to PC is facilitated by the unique peritoneal tumor microenvironment, where metastatic peritoneal seeding requires evasion of anti-tumor immunity and maintenance of a highly immunosuppressive microenvironment.

City of Hope researchers rationalise that a combined approach using Imugene’s proposed license for novel oncolytic virus CF33 armed to express an anti-PD-L1 antibody as immune modulator could specifically kill cancer cells, convert the immunologically ‘cold’ environment of PC into a ‘hot’ environment, and enhance overall efficacy of GC therapy.

“Imugene and City of Hope are committed to help improve the length and quality of life for patients with gastric cancer. We congratulate Dr. Yanghee Woo and Dr. Yuman Fong on receiving this sizable grant. It is an honour to work with the prestigious and prolific team at City of Hope to expand the development of CF33,” Imugene’s M.D. & CEO, Ms Leslie Chong said.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.